Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review

Bibliography

• PARKER WB, SHADDIX Sc, CHANG EL et al.: Effects of 2-chloro-9-(2-deoxy-2-fluoro-B-D-arabinofitranosyfiadenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate. Cancer Res. (1991) 51:2386–2394.
   PubMed Web of Science ®Google Scholar
• CARSON DA, WASSON DB, ESPARZA LM et al.: Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine. Proc. Natl. Acad. Sci. USA (1992) 89:2970–2974.
   PubMed Web of Science ®Google Scholar
• •Early work describing the ability of clofarabine to induce apoptosis in quiescent lymphocytes.
   Google Scholar
• XIE KC, PLUNKETT W: Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-13-D-arabinofitranosyl) adenine. Cancer Res. (1996) 56:3030–3037.
   PubMed Web of Science ®Google Scholar
• •Excellent description of the mechanism of action of clofarabine.
   Google Scholar
• PARKER WB, SHADDIX SC, ROSE LM et al.: Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-13-D-arabinofitranosyfiadenine, 2-chloro-9-(2-deoxy-2-fluoro-13-D-ribofitranosyfiadenine, and 2-chloro-9-(2-deoxy-2,2-difluoro-13-D-ribofitranosyfiadenine in CEM cells. Mol. Pharmacol (1999) 55:515–520.
   PubMed Web of Science ®Google Scholar
• KUMMAR S, NORONHA V, CHU E: Antimetabolites. In: Cancer: Principles and Practice of Oncology, 7th edn. Devita VT (Ed.), Lippincott Williams and Wilkins, Philadelphia, PA (2000):358–374.
   Google Scholar
• CARSON DA, WASSON DB, TAETLE R et al.: Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood (1983) 62:737–743.
   PubMed Web of Science ®Google Scholar
• GENINI D, ADACHI S, CHAO Q et al: Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood (2000) 96:3537–3543.
   PubMed Web of Science ®Google Scholar
• •Possible mechanism of apoptosis induced by nucleoside analogues.
   Google Scholar
• LOTFI K, MANSSON E, SPASOKOUKOTSKAJA T et al.: Biochemical pharmacology and resistanceto 2-chloro-2'-arabinofluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin. Cancer Res. (1999) 5:2438–2444.
   PubMed Web of Science ®Google Scholar
• MANSSON E, FLORDAL E, LILIEMARK J et al.: Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem. Pharmacol (2003) 65:237–247.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY JA, SHORTNACY-FOWLER AT, CLAYTON SD et al.: Synthesis and biologic activity of 2'-fluoro-2-halo derivatives of 9-0-D-arabinofuranosyladenine. J. Med. Chem. (1992) 35:397–401.
   PubMed Web of Science ®Google Scholar
• MARQUEZ VE, TSENG CK, KELLEY JA et al.: 2',3'-Dideoxy-2'-fluoro-ara-a. An acid stable purine nucleoside active against human immunodeficiency virus (HIV). Biochem. Pharmacol (1987) 36:2719–2722.
   Google Scholar
• GANDHI V KANTARJIAN H, FADERL S et al.: Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin. Cancer Res. (2003) 9:6335–6342.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN HM, GANDHI V, KOZUCH P et al.: Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J. Clin. Oncol. (2003) 21:1167–1173.
   PubMed Web of Science ®Google Scholar
• •Initial Phase I trial of clofarabine for solid tumours and haematological malignancies in adults.
   Google Scholar
• BONATE PL, CRAIG A. GAYNON P et al.: Population pharmacokinetics of clofarabine, a second generation nucleoside analog, in pediatric patients with acute leukemia. J. Clin. Pharmacol. (2004) 44:1309–1322.
   Google Scholar
• WARRELL RP, BERMAN E: Phase land II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J. Clin. Oncol. (1986) 4:74–79.
   PubMed Web of Science ®Google Scholar
• JEHA S, GANDHI V, CHAN KW et cll.: Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood (2004) 103:784–789.
   Google Scholar
• •First paediatric trial of clofarabine in advanced haematological malignancies.
   Google Scholar
• KANTARJIAN H, GANDHI V, CORTES J et al.: Phase II clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood (2003) 102:2379–2386.
   PubMed Web of Science ®Google Scholar
• ••Phase II study further demonstrating the activity of clofarabine in adults with advanced acute leukaemias.
   Google Scholar
• BURNETT AK, RUSSELL N, KELL JW et al.: A Phase II evaluation of single agent clofarabine as first line treatment for older patients with AML who are not considered fit for intensive chemotherapy. Blood (2004) 104(S1) (Abstr 869).
   Google Scholar
• ••Early report of clofarabine used for theinitial treatment of older patients with acute myeloid leukaemia or myelodysplastic syndrome.
   Google Scholar
• CHIAO N, BUMGARDNER A, DUVIC M: Clofarabine-induced acral erythema during the treatment of patients with myelodysplasia and acute leukemia: report of two cases. Leuk. Lymphoma (2003) 44:1405–1407.
   PubMed Web of Science ®Google Scholar
• JEHA S, GAYNON P, STEINHERZ P et al.: A Phase II, open-label study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood (2003) 102(S1): (Abstr 3277).
   Google Scholar
• JEHA S, STEINHERZ P, GAYNON P et al.: A Phase II, open-label study of clofarabine in pediatric patients with refractory or relapsed acute myelogenous leukemia. Blood (2003) 102(S1) (Abstr 2278).
   Google Scholar
• JEHA S, RAZZOUK BI, RYTTING ME et al.: Phase II trials of clofarabine in relapsed or refractory pediatric leukemia. Blood (2004) 104: 51 (Abstr 684).
   Google Scholar
• ••Summary of the Phase II data in advancedpaediatric acute leukaemia.
   Google Scholar
• COOPER T, AYRES M, NOWAK B et al.: Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother. Pharmacol. (2004) 55: 361–368.
   PubMed Web of Science ®Google Scholar
• •Describes the possible modulation of clofarabine by cytarabine.
   Google Scholar
• FADERL S, GANDHI V, O'BRIEN S et al.: Results of a Phase 1–2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood (2005) 105:940–947.
   Google Scholar
• •Initial Phase I/II study of clofarabine in combination with cytarabine.
   Google Scholar
• FADERL S, GANDHI V, VERSTOVSEK S et al.: Clofarabine plus cytarabine (ARA-C) combination is active in newly diagnosed patients age 50 with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Blood (2004) 104(S1) (Abstr 875).
   Google Scholar
• FADERL S, FERRAJOLIL A, WIERDA W et al.: Phase I study of clofarabine plus idarubicin plus cytarabine in patients with relapsed and primary refractory acute myeloid leukemia, myelodysplastic syndrome, and myeloid blast phase of chronic myeloid leukemia. Blood (2004) 104(S1) (Abstr 1809).
   Google Scholar
• RAVINDRANATH Y: Recent advances in pediatric acute lymphoblastic and myeloid leukemia. Curr. Opin. Oncol. (2003) 15:23–35.
   PubMed Web of Science ®Google Scholar
• PUI CH, EVANS WE: Acute lymphoblastic leukemia. New EngL J. Med. (1998) 339:605–615.
   PubMed Web of Science ®Google Scholar
• ESTEY E: How I treat older patients with AML. Blood (2000) 96:1670–1673.
   PubMed Web of Science ®Google Scholar
• STERNBERG A: Clofarabine Bioenvision/ ILEX. Curr. Opin. Invest. Drugs (2003) 4:1479–1487.
   PubMedGoogle Scholar
• •Excellent discussion of the development of clofarabine.
   Google Scholar
• FADERL S, GANDHI V KEATING M et al.: The role of clofarabine in hematologic and solid malignancies - development of a next-generation nucleoside analog. Cancer (2005) 103(10):19854995.
   Google Scholar
• ••Excellent review of the development,pharmacology and clinical experience with clofarabine in adults and children.
   Google Scholar